Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
26 Juli 2023 - 1:55PM
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded
with a mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs,
today announced it will hold a conference call on Wednesday, August
2, 2023, at 8:00 a.m. Eastern Time to discuss second quarter
financial results and provide a business update.
To participate in the conference call, please dial (844)
481-2838 (domestic) or (412) 317-1858 (international) and ask to be
joined into the Ardelyx call. Live audio of the conference call
will be simultaneously webcast and will be available under the
Investors section of the company's website
at www.ardelyx.com. The webcast will be archived and
available for replay for 30 days following the call.
About Ardelyx, Inc.Ardelyx was founded with a
mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs.
Ardelyx’s first approved product, IBSRELA® (tenapanor) is available
in the United States and Canada. Ardelyx is developing XPHOZAH®
(tenapanor), a novel product candidate for the control of serum
phosphorus in adult patients with chronic kidney disease (CKD) on
dialysis, which has completed three successful Phase 3 trials.
Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the
potential treatment of elevated serum potassium, or hyperkalemia, a
problem among certain patients with kidney and/or heart disease and
an early-stage program in metabolic acidosis, a serious electrolyte
disorder in patients with CKD. Ardelyx has established agreements
with Kyowa Kirin in Japan, Fosun Pharma in China and Knight
Therapeutics in Canada for the development and commercialization of
tenapanor in their respective territories. For more information,
please visit https://ardelyx.com/ and connect with us on Twitter,
LinkedIn and Facebook.
Investor and Media Contacts: Caitlin
Lowieclowie@ardelyx.com
Kimia Keshtbod kkeshtbod@ardelyx.com
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024